Name: Ginkgo Bioworks, Mammoth Biosciences among winners of NIH’s ‘Shark Tank’ for Covid-19 tests
Brand: statnews.com
SKU: statnews-com-58
Availability: OnlineOnly

critic

Ginkgo Bioworks, Mammoth Biosciences among winners of NIH’s ‘Shark Tank’ for Covid-19 tests 

preview

he National Institutes of Health selected Ginkgo Bioworks, Mammoth Biosciences, Quidel, and four other companies to receive nearly $250 million to develop new Covid-19 diagnostic tests through its Rapid Acceleration of Diagnostics program, the agency announced Friday.Three of the tests are intended to be processed at pharmacies or doctor’s offices; four are tests meant to be run in clinical labs. The money is coming from a through the same law that created the Paycheck Protection Program.The goal of the program, often abbreviated to RADx, is to add millions of tests per day to the U.S.’s current testing capacity by September 2020, which is . Ultimately, the program hopes its awardees will add 6 million tests per day by the end of the year.advertisement“September is an extremely ambitious goal,” said NIH Director Francis Collins. “But we do believe that demand for testing will continue to rise in the fall.”Twenty other companies are still being considered for funding through the program, the release noted.advertisementThe seven projects were selected from a pool of 100 ideas that went through a “Shark Tank” process, as the NIH has repeatedly described it. Originally, National Institute of Biomedical Imaging and Bioengineering Director Bruce Tromberg said about five programs would ultimately be selected.Quidel, Mesa Biotech, and Talis Biomedical are developing point-of-care tests, while Ginkgo Bioworks, Mammoth Biosciences, Helix, and Fluidigm (), are developing lab-based tests.None of the funded projects are brand new; each company has either received an emergency use authorization for its test from the Food and Drug Administration or has submitted an application for an EUA.And in some cases, the companies have already raised money for these projects elsewhere.Mammoth, which is making a CRISPR-based test, is also working with GlaxoSmithKline’s consumer health division on a Covid-19 test. (The value of that collaboration was not disclosed when it was .) Ginkgo Bioworks’ efforts to automate more of the lab work needed to run a Covid-19 test in May from the sequencing company Illumina as well as a hedge fund and a private equity firm. And Quidel already has an EUA for its test.What the NIH funding offers is scale, according to Marc Stapley, Helix’s president and CEO. He said the money will allow his company to “move far faster to ramp up our capacity than we otherwise would have.”“Good to great is the idea here,” said Collins.Comments are closed.advertisementYou've been selected! Subscribe to STAT+ for less than $2 per daySubscribe to STAT+ for less than $2 per dayUnlimited access to the health care news and insights you need

he National Institutes of Health selected Ginkgo Bioworks, Mammoth Biosciences, Quidel, and four other companies to receive nearly $250 million to develop new Covid-19 diagnostic tests through its Rapid Acceleration of Diagnostics program, the agency announced Friday.Three of the tests are intended to be processed at pharmacies or doctor’s offices; four are tests meant to be run in clinical labs. The money is coming from a through the same law that created the Paycheck Protection Program.The goal of the program, often abbreviated to RADx, is to add millions of tests per day to the U.S.’s...

public

sheridan_kate

Kate Sheridan

Reporting from the frontiers of health & medicine. http://statnews.com

statnews.com

Credible

Speculation

Anecdotal Evidence

Generalization

Stacking the Deck

Appeal to Authority

Straw Man

Slippery Slope

Emotional Appeal

Red Herring

False Dilemma

Illogical

Moral Equivalency

Ad Hominem

Correlation w/o Causation

Semantics

Begging the Question

Faulty Analogy

Non Sequitur

Bandwagon

Dogmatism

Failing Occam's Razor

Biased

Pure Opinion

Hit Piece

Racial Bias

National Bias

Religious Bias

Financial Incentive

Political Agenda

Gender Bias

Misused Image/Video

Study Misinterpreted

Mistake

Misused Term

Science Misrepresented

Factual Error

Satire

Surface Level

Lack of Reliable Sources

Sensational

Not Credible

Investigative

Balanced

Well Sourced

Great Context

sports

entertainment

U.S.

international

business

technology

science

culture

politics

media

health

Ginkgo Bioworks, Mammoth Biosciences among winners of NIH’s ‘Shark Tank’ for Covid-19 tests

No article scores yet.

CRITIC REVIEWS

PUBLIC REVIEWS